523P Treatment duration and subsequent treatments of first-line (1L) CDK4/6i plus aromatase inhibitor (AI) for HR+/HER2- metastatic breast cancer (MBC) in US routine clinical practice
Year: 2025
Type: article
Study design: Observational Study
Source: Annals of Oncology
Authors: A.M. Brufsky, R.M. Layman, X. Liu, B. Li, L. McRoy, A. Cohen, M. Estevez, P.H. Cottu, M.A.M. Thill, G. Curigliano, H.S. Rugo
Institutions: UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, The University of Texas MD Anderson Cancer Center, Pfizer (United States), Flatiron Health (United States), Université Paris Cité, Institut Curie, Agaplesion Markus Hospital, University of Milan, European Institute of Oncology, City Of Hope National Medical Center, City of Hope
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Pfizer
OpenAlex ID: W4415941529